It is never too late to stop smoking. Applying working estimates of smoking cessation on five-year overall survival gains after a cancer diagnosis.
1/5 보강
[BACKGROUND] Detailed data on five-year overall survival (5Y-OS) in relation to smoking cessation after a cancer diagnosis are sparse.
- 연구 설계 cohort study
APA
El-Haddad N, Li Y, et al. (2025). It is never too late to stop smoking. Applying working estimates of smoking cessation on five-year overall survival gains after a cancer diagnosis.. Cancer epidemiology, 96, 102775. https://doi.org/10.1016/j.canep.2025.102775
MLA
El-Haddad N, et al.. "It is never too late to stop smoking. Applying working estimates of smoking cessation on five-year overall survival gains after a cancer diagnosis.." Cancer epidemiology, vol. 96, 2025, pp. 102775.
PMID
40106868 ↗
Abstract 한글 요약
[BACKGROUND] Detailed data on five-year overall survival (5Y-OS) in relation to smoking cessation after a cancer diagnosis are sparse. Implementation of smoking cessation in cancer treatment centres is also sub-optimal. The aim is to provide working, numeric estimates of 5Y-OS outcomes in relation to quitting smoking to help inform patients with cancer.
[METHODS] 5Y-OS data and hazard ratios (HR) from a moderately sized cohort study from Japan were used to derive survival benefits on Australian cancer survival scenarios ranging from 10 % to 90 % 5Y survival, using standard epidemiological formulas comparing survival in those who recently quit around the time of their cancer diagnosis in comparison to those who continued to smoke.
[RESULTS] In a scenario of a cancer type with 90 % 5 y survival e.g. breast, prostate cancer, or melanoma, quitting smoking shows a gain in 5Y-OS of 10 %, and a gain in median survival of 2.1 years. In a scenario of 20 % 5 y survival (e.g. lung, liver, brain, or oesophageal cancer) recent quitting shows a 5Y-OS gain of 2 %, and a median survival gain of three months.
[CONCLUSION] The greater the survival at presentation, the greater the gain by quitting smoking. Future research should aim to produce estimates based on real-world data.
[METHODS] 5Y-OS data and hazard ratios (HR) from a moderately sized cohort study from Japan were used to derive survival benefits on Australian cancer survival scenarios ranging from 10 % to 90 % 5Y survival, using standard epidemiological formulas comparing survival in those who recently quit around the time of their cancer diagnosis in comparison to those who continued to smoke.
[RESULTS] In a scenario of a cancer type with 90 % 5 y survival e.g. breast, prostate cancer, or melanoma, quitting smoking shows a gain in 5Y-OS of 10 %, and a gain in median survival of 2.1 years. In a scenario of 20 % 5 y survival (e.g. lung, liver, brain, or oesophageal cancer) recent quitting shows a 5Y-OS gain of 2 %, and a median survival gain of three months.
[CONCLUSION] The greater the survival at presentation, the greater the gain by quitting smoking. Future research should aim to produce estimates based on real-world data.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.